|Videos|August 13, 2020
ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer
Advertisement
Key opinion leaders discuss various trial data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting regarding the management of metastatic HER2-positive breast cancer.
Data from the following clinical trials is discussed:
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).(Lin, ASCO 2020 Abstract 1005)
The recent FDA approvals for relapsed refractory HER2+ MBC:
Trastuzumab deruxtecan in Previously Treated HER2+ Breast Cancer: DESTINY-BREAST01 (Modi, NEJM 2020)
Fam-trastuzumab deruxtecan-nxki
Tucatinib
Neratinib
The potential role of trastuzumab deruxtecan in HER2-low expressing tumors: phase 3, DESTINY-Breast04; NCT03734029
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Obesity may increase breast cancer risk partly by removing a natural defense.
Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5